Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
commissioner
3
×
detroit blog main
detroit top stories
fda
3
×
gene editing
ipo
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
3
×
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
scott gottlieb
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
celgene
ceo
clinical study
crispr
democrats
failure
glaxosmithkline
indiana blog main
indiana top stories
shutdown
What
bio
roundup
crispr
medicine
allogene
big
biopharma
bosley's
bosley’s
bridge
bucks
cancer
car
cas
celgene
ceo
colleagues
crime
departure
diversity
editas
exit
exome
government
guiding
health
hot
hundreds
immunotherapy
industry
investors
ipo
juno
katrine
million
moves
nearly
new
personnel
policy
Language
Current search:
commissioner
×
" raleigh-durham top stories "
×
fda
×
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
Bio Roundup: $74B for Celgene, Two CAR-T Tales, Ready for SF & More
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More